Neurodegenerative disease management最新文献_第3页

Effect of neuromodulation on neurogenic bladder in women with multiple sclerosis: a pilot randomized controlled trial. 神经调节对多发性硬化症女性神经源性膀胱的影响：一项随机对照试验。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-01 Epub Date: 2025-04-11 DOI: 10.1080/17582024.2025.2488712

Pınar Atak Çakir, Vahit Güzelburç, Erkingül Birday, Lütfü Hanoğlu, Fatma Mutluay

{"title":"Effect of neuromodulation on neurogenic bladder in women with multiple sclerosis: a pilot randomized controlled trial.","authors":"Pınar Atak Çakir, Vahit Güzelburç, Erkingül Birday, Lütfü Hanoğlu, Fatma Mutluay","doi":"10.1080/17582024.2025.2488712","DOIUrl":"10.1080/17582024.2025.2488712","url":null,"abstract":"Aim: Neurogenic overactive bladder symptoms are very common in patients with multiple sclerosis (MS). In current approaches, neuromodulation methods are preferred. To investigate the effect of transcutaneous posterior tibial nerve stimulation (TPTNS) and repetitive transcranial magnetic stimulation (rTMS) on neurogenic overactive bladder symptoms in patients with MS.Patients methods: Sixteen female MS patients with neurogenic overactive bladder were randomized into TPTNS and rTMS groups for a pilot study. Treatment was blinded to the investigator and statistician but not to patients and physiotherapists. Treatments were applied for a total of 10 sessions over two consecutive weeks. The primary outcome of the study was urodynamic testing, and secondary outcomes were Overactive Bladder Questionnaire-V8 (OAB-V8), Incontinence Severity Index (ISI), Incontinence Quality of Life Scale (I-QOL) and voiding diary applied before and after treatment.Results: In TPTNS and rTMS groups, urodynamic parameters did not show any statistically significant change within and between groups (p > 0.05). Only nocturia frequency provided statistically significant improvement in the TPTNS group compared to the rTMS group (p = 0.01). OAB-V8, ISI and I-QOL parameters did not change significantly between groups (p > 0.05).Conclusion: Although TPTNS and rTMS methods are not superior to each other, they can be used to reduce symptoms and improve quality of life.Clinical trial registration: NCT05312138.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"57-64"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigation of the significance of quantitative MRI parameters in differentiating PSP from MSA patients. 定量MRI参数对鉴别PSP与MSA的意义探讨。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-01 Epub Date: 2025-03-27 DOI: 10.1080/17582024.2025.2481817

Halil Onder, Aynur Turan, Fatmanur Ugur, Selcuk Comoglu

{"title":"Investigation of the significance of quantitative MRI parameters in differentiating PSP from MSA patients.","authors":"Halil Onder, Aynur Turan, Fatmanur Ugur, Selcuk Comoglu","doi":"10.1080/17582024.2025.2481817","DOIUrl":"10.1080/17582024.2025.2481817","url":null,"abstract":"Objective: To investigate the utility of quantitative MRI parkinsonism indices in discriminating between progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) patients.Methods: In our study including PSP and MSA patients, we calculated the radiological measures including superior cerebellar peduncle width, middle cerebellar peduncle width, third ventricle width, 3rdV/bifrontal width, pons/mesencephalon (P/M) ratio, P/M ratio 2.0, magnetic resonance parkinsonism index (MRPI), and MRPI 2.0 values. We also constituted a PMS scale to increase the discrimination power.Results: Comparisons between PSP and MSA patients revealed significant differences in the mesencephalon area, third ventricle width, 3rdV/bifrontal width, P/M ratio, P/M ratio 2.0, MRPI, and MRPI 2.0 values (p < 0.01 for all). The AUC values were acceptable for the third ventricle width, the 3rdV/bifrontal width ratio, the P/M ratio, the P/M 2 ratio, the MRPI and the MRPI-2. In distinguishing PSP, 0 points on the PMS scale had a negative predictive value (NPV) of 91%, whereas 3 points had a positive predictive value (PPV) of 85.7%.Conclusion: None of the MRI parameters reached a good diagnostic AUC in distinguishing PSP from MSA. However, the PMS scale we propose in this study may provide high PPVs and NPVs for differential diagnosis during desk-based evaluation.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"89-96"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143720776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The calmodulin hypothesis of neurodegenerative diseases: searching for a common cure. 神经退行性疾病的钙调素假说：寻找共同治疗方法。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-01 Epub Date: 2025-04-02 DOI: 10.1080/17582024.2025.2488230

Danton H O'Day

引用次数: 0

Shared decision-making for multiple sclerosis using the MS-SUPPORT tool: a plain language summary. 多发性硬化症的共同决策使用MS-SUPPORT工具：一个简单的语言总结。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-01 Epub Date: 2025-05-07 DOI: 10.1080/17582024.2025.2493028

Nananda F Col, Andrew J Solomon, Enrique Alvarez, Lori Pbert, Carolina Ionete, Idanis Berrios Morales, Jennifer Chester, Christen Kutz, Crystal Iwuchukwu, Terrie Livingston, Vicky Springmann, Hannah Col, Long Ngo

引用次数: 0

Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice. ofatumumab在临床实践中的有效性、持久性、耐受性和安全性。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-02-01 Epub Date: 2025-01-21 DOI: 10.1080/17582024.2025.2452150

Moein Amin, Tucker Harvey, Dan Michael Pineda, Ming-Hui Tai, Qiujun Shao, Brandon Brown, Abhijit Gadkari, Brandon Moss, Devon S Conway, Carrie M Hersh

{"title":"Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice.","authors":"Moein Amin, Tucker Harvey, Dan Michael Pineda, Ming-Hui Tai, Qiujun Shao, Brandon Brown, Abhijit Gadkari, Brandon Moss, Devon S Conway, Carrie M Hersh","doi":"10.1080/17582024.2025.2452150","DOIUrl":"10.1080/17582024.2025.2452150","url":null,"abstract":"Aims: To describe the 12-month effectiveness, persistence, tolerability, and safety of ofatumumab (OMB), a highly effective disease-modifying therapy (DMT) for relapsing multiple sclerosis (MS), in a real-world MS population.Patients & methods: Electronic medical records of patients starting OMB from October 2020 to August 2022 at two comprehensive MS centers were reviewed. Demographics and disease characteristics and 6- and 12-month clinical, patient-reported, and radiologic outcome measures were analyzed.Results: A total of 175 patients started OMB with mean age 44.9 (SD 10.4) and disease duration 13.6 (SD 9.6) years. The cohort was 74% female, included 81% White and 13% Black American patients, and consisted of 80% relapsing-remitting MS or clinically isolated syndrome. Most (87%) had prior DMT exposure with 38% switching from high efficacy DMT. Over 12 months, 9.7% discontinued OMB (mean 117 days, SD 99.2), with tolerability issues being the most common reason. Thirty-nine (22%) had relapses in the year before starting OMB. By 12 months, only 1 relapse had occurred after approximately 4 months post-treatment initiation.Discussion: This real-world study demonstrated that OMB is highly effective with robust persistence and good safety and tolerability by 12-month follow-up. Further analyses are planned to examine longer-term outcomes.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"27-36"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in the management of Alzheimer's disease. 阿尔茨海默病的治疗进展。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-02-01 Epub Date: 2025-02-06 DOI: 10.1080/17582024.2025.2463313

Maheen Nawaz, Ahmed Ali Khan, Muhammad Shaheer Bin Faheem

引用次数: 0

Friedreich ataxia: what can we learn from non-GAA repeat mutations? 弗里德里希共济失调：我们能从非GAA重复突变中学到什么？

IF 2.3

Neurodegenerative disease management Pub Date : 2025-02-01 Epub Date: 2025-01-15 DOI: 10.1080/17582024.2025.2452147

David R Lynch, M Shen, Robert B Wilson

引用次数: 0

Economic evaluation of mHealth solutions in PD: where do we stand? PD中移动医疗解决方案的经济评估：我们在哪里？

IF 2.3

Neurodegenerative disease management Pub Date : 2025-02-01 Epub Date: 2025-02-18 DOI: 10.1080/17582024.2025.2467020

Foivos S Kanellos, Ermioni Petkou, Spyridon Konitsiotis, Yannis V Simos, Lampros Lakkas, Dimitrios Peschos, Konstantinos I Tsamis

引用次数: 0

Investigation of nonmotor symptoms and their clinical correlates in patients with Parkinson's disease. 帕金森病患者非运动症状及其临床相关性的研究

IF 2.3

Neurodegenerative disease management Pub Date : 2025-02-01 Epub Date: 2025-03-17 DOI: 10.1080/17582024.2025.2468145

H Onder, S Comoglu

{"title":"Investigation of nonmotor symptoms and their clinical correlates in patients with Parkinson's disease.","authors":"H Onder, S Comoglu","doi":"10.1080/17582024.2025.2468145","DOIUrl":"10.1080/17582024.2025.2468145","url":null,"abstract":"Background: In this study, we aimed to investigate the clinical features of a large group of patients with Parkinson's disease (PD), paying particular attention to the nonmotor symptom (NMS) load. Secondly, we aimed to investigate the clinical correlates of NMSs using the results of various clinical assessments.Methods: Data from all PD patients who visited our movement disorders clinic between January 2023 and March 2024 were retrospectively reviewed. We included the data of all patients whose information regarding clinical features and extensive scale results were available.Results: Overall, we included data from 285 PD patients with a mean age of 64.5 ± 10.0 years (F/M = 119/166). The median scores of the MDS-UPDRS subparts were 9 for MDS-UPDRS-1 and 30 for MDS-UPDRS-3 (off). The median NMSS score was 38 (range: 229), and 46% of the patients had severe to very severe disease in terms of NMS burden. The regression analyses revealed the MDS-UPDRS 3 score, FES-I score, and RBD (0.9772 + 0.453*MDS-UPDRS 3 + 0.724 * FES-I + 15.192*RBD) as predictors of the NMS scale.Conclusions: We found a very high NMS burden in our PD cohort. Remarkably, RBD, motor stage, and concern about falling were found to correlate with NMS load.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"47-55"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-02-01 Epub Date: 2025-02-20 DOI: 10.1080/17582024.2025.2468543

引用次数: 0